FA affects an estimated 20,000 individuals globally. Approximately 5,000 of those affected with FA live in the United States and the majority of the remainder reside in Europe.
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024 Selected by Food and Drug Administration (FDA) to participate in Support
Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside cells to treat devastating rare diseases that currently have limited or no treatments available.
Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia.